Here’s why Pfizer is revising its revenue forecasts

Here’s why Pfizer is revising its revenue forecastsListen(2 min)Listen(2 min)Pfizer said revenue should come in at the lower end of its guidance this year, and it expects less revenue in 2026 than in 2025, as the drugmaker’s efforts to remake its business continue to play out. The company’s stock PFE was up about 1% in premarket trading on Tuesday. About the AuthorJaimy Lee is a healthcare reporter and editor for MarketWatch. She is based in New York.Copyright © 2025 MarketWatch, Inc. All rights reserved.